[go: up one dir, main page]

GB202318087D0 - Antisense oligonucleotides for the treatment of liver disease - Google Patents

Antisense oligonucleotides for the treatment of liver disease

Info

Publication number
GB202318087D0
GB202318087D0 GBGB2318087.0A GB202318087A GB202318087D0 GB 202318087 D0 GB202318087 D0 GB 202318087D0 GB 202318087 A GB202318087 A GB 202318087A GB 202318087 D0 GB202318087 D0 GB 202318087D0
Authority
GB
United Kingdom
Prior art keywords
treatment
liver disease
antisense oligonucleotides
antisense
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2318087.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProQR Therapeutics II BV
Original Assignee
ProQR Therapeutics II BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProQR Therapeutics II BV filed Critical ProQR Therapeutics II BV
Priority to GBGB2318087.0A priority Critical patent/GB202318087D0/en
Publication of GB202318087D0 publication Critical patent/GB202318087D0/en
Priority to CN202480022520.4A priority patent/CN121002181A/en
Priority to AU2024246572A priority patent/AU2024246572A1/en
Priority to PCT/EP2024/058159 priority patent/WO2024200472A1/en
Priority to EP24715752.2A priority patent/EP4688143A1/en
Priority to KR1020257030021A priority patent/KR20250167580A/en
Priority to MX2025011322A priority patent/MX2025011322A/en
Ceased legal-status Critical Current

Links

GBGB2318087.0A 2023-03-27 2023-11-27 Antisense oligonucleotides for the treatment of liver disease Ceased GB202318087D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2318087.0A GB202318087D0 (en) 2023-11-27 2023-11-27 Antisense oligonucleotides for the treatment of liver disease
CN202480022520.4A CN121002181A (en) 2023-03-27 2024-03-26 Antisense oligonucleotides for treating liver disease
AU2024246572A AU2024246572A1 (en) 2023-03-27 2024-03-26 Antisense oligonucleotides for the treatment of liver disease
PCT/EP2024/058159 WO2024200472A1 (en) 2023-03-27 2024-03-26 Antisense oligonucleotides for the treatment of liver disease
EP24715752.2A EP4688143A1 (en) 2023-03-27 2024-03-26 Antisense oligonucleotides for the treatment of liver disease
KR1020257030021A KR20250167580A (en) 2023-03-27 2024-03-26 Antisense oligonucleotides for the treatment of liver disease
MX2025011322A MX2025011322A (en) 2023-03-27 2025-09-24 Antisense oligonucleotides for the treatment of liver disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2318087.0A GB202318087D0 (en) 2023-11-27 2023-11-27 Antisense oligonucleotides for the treatment of liver disease

Publications (1)

Publication Number Publication Date
GB202318087D0 true GB202318087D0 (en) 2024-01-10

Family

ID=89429168

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2318087.0A Ceased GB202318087D0 (en) 2023-03-27 2023-11-27 Antisense oligonucleotides for the treatment of liver disease

Country Status (1)

Country Link
GB (1) GB202318087D0 (en)

Similar Documents

Publication Publication Date Title
IL288920A (en) Glycolate oxidase inhibitors for the treatment of disease
GB201714027D0 (en) Antisense oligonucleotides for the treatment of huntington's disease
AU2024246572A1 (en) Antisense oligonucleotides for the treatment of liver disease
AU2023390632A1 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
IL289440A (en) Process for the deprotection of oligonucleotides
GB202318087D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202304438D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202502333D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202414347D0 (en) Antisense oligonucleotides for the treatment of liver disease
CA3286425A1 (en) Antisense oligonucleotides for the treatment of liver disease
GB202306756D0 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
GB202218585D0 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
IL319679A (en) Antisense oligonucleotides for the treatment of canavan disease
GB202502170D0 (en) Antisense oligonucleotides for the treatment of disease
GB202418028D0 (en) Antisense oligonucleotides for the treatment of fatty liver disease
GB202405813D0 (en) Antisense oligonucleotides for the treatment of fatty liver disease
GB202316851D0 (en) Antisense oligonucleotides for the treatment of moyamoya disease
GB202502332D0 (en) Antisense oligonucleotides for the treatment of liver cancer
GB202502189D0 (en) Antisense oligonucleotides for the treatment of liver cancer
GB202404661D0 (en) Antisense oligoncleotides for the treatment of liver disease
CA3294368A1 (en) Antisense oligonucleotides for the treatment of neurodegenerative disease
GB202313645D0 (en) Antisense oligonucleotides for the treatment of metabolic disorders
GB202410081D0 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
GB202306060D0 (en) Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202217580D0 (en) Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)